The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.

HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

Freiburg-Prague research collaboration achieves scientific breakthrough in understanding cell division. The international research collaboration has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules.

Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.

Max Planck scientists will present a low-field magnetic resonance imaging (MRI) scanner in Lindau. Two researchers from the MPI for Biological Cybernetics in Tübingen, Germany, will present a model of a new low-field MRI system. It combines hyperpolarization with imaging techniques that can be run at low magnetic field strengths. The quality of the MRI images can be enhanced with the help of artificial intelligence.

For her ground-breaking scientific studies in the field of synthetic biology, the 2024 Alfried Krupp Advancement Award is to go to Prof. Dr Kerstin Göpfrich. The award, endowed with one million euros in funding, is granted annually by the Alfried Krupp von Bohlen und Halbach Foundation to young academics holding their first professorship in the natural and engineering sciences.

CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

Researchers from the University of Heidelberg have published a study on more than 60,000 patients in the renowned journal Lancet Digital Health, demonstrating the potential of AI in cardiac medicine.

BioRegio STERN Management GmbH is a partner in the new RehAllianCE project, which is being funded by the EU as part of the Interreg CENTRAL EUROPE program. The focus is on the use of new technologies in rehabilitation to improve patient care. The aim is to increase the innovation capacities of SMEs so that aids such as rehabilitation robots, exoskeletons etc. can be used more quickly.

Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.

Baden-Württemberg receives the EU Commission's "Regional Innovation Valley" label - 01/07/2024

Customised healthcare for all: BIOPRO is a partner in the EU project PRECISEU

The EU research project PRECISEU, which started in June 2024 and will run for five years, aims to connect innovation ecosystems across Europe and advance personalised medicine throughout Europe. BIOPRO Baden-Württemberg is one of 25 partner organisations from 11 European countries that are working on the further development of customised healthcare as part of the research project.

Researchers at University of Galway, the Heidelberg Institute for Theoretical Studies (HITS) Heidelberg University, and Heidelberg University Hospital have created digital babies to better understand infants’ health in their critical first 180 days of life. The international team created computer models that simulate the unique metabolic processes of each baby. The models can help to better understand rare metabolic diseases.

How can we use artificial intelligence (AI) to make comprehensible medical decisions? A new project at the University of Mannheim, which has received funding from the Federal Ministry of Education and Research (BMBF), will analyze this question.

At the finale of the Cyber Valley Days, and Science Minister Petra Olschowski opened the ELLIS Institute Tübingen, heralding the next phase of the AI Innovation Campus. With the world's first ELLIS Institute, Cyber Valley is gaining further radiance. Olschowski also announced at the ceremony that the Karlsruhe Institute of Technology (KIT) is joining the Cyber Valley Community.

Researchers from the Max Planck Institute for Biology Tübingen developed the groundbreaking tool SynTracker. SynTracker expands traditional microbial analysis by considering genomic structural variation to complement existing SNP-based methods. This innovation reveals more precision and depths of microbial strain diversity and evolution.

Gender-specific differences - 18/06/2024

Gender medicine: Why is good healthcare not a matter of course for everyone?

Gender medicine is the study of gender-specific health differences. Many diseases manifest themselves differently in men and women and therapies do not always have the same effect depending on the sex of the patient being treated. There is currently not enough data on these differences. Research teams including the one led by Professor Dr. Dr. Sonja Loges from the University Medical Centre Mannheim and the DKFZ are seeking to change this.

Humboldt Research Award winner Prof. Hao Yan has been conducting research at the 2nd Institute of Physics at the University of Stuttgart since May. He is regarded as one of the world's leading experts in the field of DNA nanotechnology. "My work has many points of commonality with the topics that my colleagues in Stuttgart are focusing on," says Yan. "I have therefore been cooperating with Professor Laura Na Liu's working…

Printing a new cornea during an operation to restore a patient’s eyesight: This groundbreaking step in the fight against corneal disorders is set to become reality with a laser based process using personalized bioink. The method was developed by researchers at the Karlsruhe Institute of Technology (KIT) in collaboration with Carl Zeiss Meditec AG and Evonik Healthcare. Their project won the idea award in this year’s NEULAND innovation contest.

Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing.